Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine
Conditions
Interventions
Atogepant
Placebo for Atogepant
Locations
95
China
Chinese PLA General Hospital /ID# 267141
Beijing, Beijing Municipality, China
Nanfang Hospital - Southern Medical University /ID# 268510
Guangzhou, Guangdong, China
Hebei General Hospital /ID# 267663
Shijiazhuang, Hebei, China
Renmin Hospital of Wuhan University /ID# 267671
Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University /ID# 267885
Suzhou, Jiangsu, China
Shaanxi Provincial PeopleS Hospital /ID# 267827
Xi'an, Shaanxi, China
Start Date
February 10, 2025
Primary Completion Date
February 1, 2027
Completion Date
July 1, 2027
Last Updated
March 6, 2026
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions